

Whitehead Institute

personal

The visit with you + Ken last month was certainly very productive.

You should know that David Baltimore is far and away the front runner as director - appointment, and he will have a major role in further choices and discussions. My assay of site preferences at this time - and this is subject to modulation by other aspects of a concordat - is:

	Jacks	Dave	(SL: re social utility)
Stanford	2	2	1
MIT	3	1	3
R.U.	1	3	2

We (RU) will, I am sure, make some offer to Jacks + Dave that will at least roughly match what we discussed for



Joshua Lederberg
President
The Rockefeller University
New York, N.Y. 10021
(212) 360-1234

ORIG.
 COPY

RETAINED

- REPLY FORM -

Stanford. But the different valuation of real estate makes it hard to generate a symmetrical perspective. Obviously much hinges on what Dave can get from MIT that would match his preferences. But I think he would seriously consider alternatives if that doesn't work out.

So don't let this get to be torpedoed at Stanford - for the wrong reasons - as happened last time.

The important goal is to be sure that \$150M+ does come to biomedical research, no matter where.

Yours,
J

CC: Ken Melmon

Joshua Lederberg
President
The Rockefeller University
New York, N.Y. 10021
(212) 360-1234

ORIG.
 COPY

RETAINED

- REPLY FORM -